App-Quantinova.ai

Predictors for detecting chronic respiratory diseases in population surveys: a pilot study for RESPIRE 4CCORD study

Dhiraj Agarwal - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

The impact of Covid-19 on hospital length of stay and resources: an experience from a tertiary respiratory centre in the UK

Ran Wang - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

The social and structural determinants of tuberculosis incidence trends in 116 countries from 2005-2015: an ecological study

Fiona Koeltringer - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Prevalence of Eosinophilia in Patients with Tuberculosis

Vasanth Naidu - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

Chlorpheniramine

The effects of national lockdown on incidence of acute exacerbation of chronic obstructive pulmonary disease

Richard Cooper - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

A method of selecting most significant biochemical parameters in a given clinical setting in COVID-19

Swati Purohit Joshi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Assessment of the role of CT severity score in COVID-19 outcome prediction in a large Indian cohort

Swati Purohit Joshi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Influence of farm environment on asthma during the life-course: a population-based birth cohort study in Northern Finland

Marko Kantomaa - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Association of asthma diagnosis with chronic airflow obstruction: a multi-site cross-sectional study

Octavia Mulhern - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

An international Mendelian Randomization study of BMI and ICS response in children

Cristina Longo - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Distribution of biomarkers in severe asthma and severe uncontrolled asthma

Bo Ding - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

Nitric oxide

An estimate of the European prevalence of COPD in 2050

Adam Benjafield - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Predictions of post-bronchodilator airflow obstruction by longitudinal asthma and wheeze patterns in middle-age

Jennifer Perret - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Forced Vital Capacity and Mortality in The BOLD Study: Preliminary Findings

Emmanouil Bagkeris - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Clinical characteristics, mortality rates and causes of death in non-exacerbating COPD patients. A longitudinal cohort analysis of UK primary care data

Alexandra Lenoir - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

The impact of ethnicity on disease presentation and control in severe asthma

John Busby - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Assesing the impact of corticosteroids on bone health in people with asthma: a systematic review and meta-analysis

Christos Chalitsios - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on a Functional Respiratory Imaging (FRI) Model

Mark Nagel - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

fluticasone / salmeterol powder

IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain

Victoria Paly - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Fluticasone furoate

Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial

Dhvani Shah - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Fluticasone furoate

Filters

45280 Abstracts